Management and follow-up for patients with advanced lung cancer
A Multicenter, Randomized, Open, Parallel Grouping, Investigator-initiated Study Evaluating the Long-term Benefit of Patients With Locally Advanced/Metastatic Non-small Cell Lung Cancer Followed up Using a Patient-wide Management Platform
This study is testing a new patient management system to see if it can help people with advanced lung cancer live longer and feel better during their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1268 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Qianfoshan Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT05339568 on ClinicalTrials.gov |
What this trial studies
This project aims to explore the effectiveness of a patient process management platform in prolonging survival and improving the quality of life for individuals with locally advanced or metastatic non-small cell lung cancer (NSCLC). The study addresses the challenges faced by patients during treatment, including complications and adherence to medication regimens. By providing comprehensive follow-up and management, the study seeks to enhance patient compliance and alleviate psychological burdens associated with cancer treatment. The approach emphasizes the importance of continuous support and communication between healthcare providers and patients.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old diagnosed with stage IIB, III, or IV non-small cell lung cancer who are not suitable for radical treatment.
Not a fit: Patients with mental illness or those expected to undergo radical surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve survival rates and quality of life for patients with advanced lung cancer.
How similar studies have performed: While the specific approach of this study may be novel, similar studies focusing on patient management and follow-up have shown promise in improving outcomes for cancer patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Fully understand the research and voluntarily sign the informed consent form (ICF) 2. Male or female subjects who are over 18 years old (inclusive) at the time of signing the informed consent form. 3. The subject is diagnosed pathologically or cytologically with non-small cell lung cancer(NSCLC). 4. According to the 8th edition of the American Joint Committee on Cancer \[AJCC\], it is classified as stage IIB, stage III, stage IV NSCLC. 5. Not suitable for radical treatment or refuse surgery. 6. The life expectancy is not less than 3 months. 7. Be able to use a smartphone. Exclusion Criteria: 1. Patients with mental illness. 2. Presence of any other malignant tumor. 3. Patients who are expected to undergo radical surgery. 4. Currently participating in clinical trials. 5. Subjects who judged by the investigator to be unsuitable to participate in the trial.
Where this trial is running
Jinan, Shandong
- The First Affiliated Hospital of Shandong First Medical University — Jinan, Shandong, China (Recruiting)
Study contacts
- Principal investigator: Jiandong ZHANG — Shandong First Medical University
- Study coordinator: Jiandong ZHANG
- Email: zhangjd165@sina.com
- Phone: (+86531)89268118
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.